PharmEvo Private

What PharmEvo Private does

PharmEvo (Pvt.) Ltd. is a Karachi-headquartered, privately held Pakistani pharmaceutical company founded in 1999, operating across four product verticals: branded generic pharmaceuticals, nutraceuticals, consumer health products, and medical devices. Its pharmaceutical portfolio of 86 SKUs spans cardiovascular, anti-diabetic, respiratory, anti-infective, CNS/psychiatry, gastroenterology, orthopedics/pain management, women's health, and oncology (including monoclonal antibodies such as bevacizumab, rituximab, and trastuzumab), supported by a 217,800 sq. ft. GMP-, GLP-, ISO 9001/14001/45001-certified manufacturing facility in Port Qasim with dedicated Cephalosporin, Non-Cephalosporin, and Nutraceutical plants producing multiple dosage forms including tablets, capsules, liquids, sachets, injectables, dry powder suspensions, and dry powder inhalers.

The company ranks among the top 20 pharmaceutical companies in Pakistan and distributes to 37 international markets across South Asia, the Middle East, Central Asia, Caucasus, multiple African regions, Central America, Southeast Asia, and Southeast Europe through affiliate and partner networks. Its go-to-market combines a domestic field sales force targeting physicians and pharmacies, an e-commerce platform (mypharmevo.pk) for direct-to-consumer access, OMRON medical device distribution, and contract manufacturing under international partner brand names. Revenue is generated primarily from one-time branded-generic pharmaceutical sales, with secondary streams from nutraceuticals, consumer health, hardware (medical devices), and professional services (contract manufacturing and pharmacovigilance/MedGuard).

PharmEvo is led by Managing Director M. Haroon Qassim (former chairman of the Pakistan Pharmaceutical Manufacturers Association) and CEO Syed Jamshed Ahmed, with an 18-person leadership team covering commercial, marketing, technical operations, supply chain, finance, medical affairs, and digital functions. The company distinguishes itself through cause-based, ethically marketed disease awareness initiatives (Discovering Diabetes with PES, Discovering Hypertension, Discovering PCOS), HCP engagement platforms (PHARMASSIST, ILE, eDR, Research Forum), and an in-house Learning Management System. No external institutional investors, parent company, or public listing is evidenced in the source material.

Name

PharmEvo Private

Legal name

PharmEvo (Pvt.) Ltd.

Website

https://pharmevo.biz

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

PharmEvo (Pvt.) Ltd. is a Karachi-based private Pakistani pharmaceutical company founded in 1999, ranked among the country's top 20, manufacturing branded generics, nutraceuticals, consumer health products, and medical devices across 37 international markets.

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Branded generic pharmaceuticals
• Nutraceutical supplements
• Medical devices
• Contract manufacturing
• Pharmaceutical manufacturing

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Branded Generic Pharmaceuticals: Core pharmaceutical business offering quality branded generic medicines across therapeutic areas including Cardiovascular, Orthopedics, Endocrinology, Respiratory, and Anti-Infective segments. Products sold across 37 international markets.
2. Nutraceutical Products: Scientific-based nutraceutical products including vitamins, supplements, and health products manufactured in dedicated modernistic facility.
3. Consumer Health Products: Over-the-counter consumer health products including medical devices, wellness products, and health monitoring equipment.
4. Medical Devices: Medical devices including blood glucose monitors, thermometers, pulse oximeters, blood pressure monitors, body composition monitors, and nebulizers.
5. Contract Manufacturing: Contract manufacturing under International Partner brand name as part of collaborative business models for expansion.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

PharmEvo develops, manufactures, and markets a diversified portfolio of 107+ branded generic pharmaceutical products, nutraceuticals, consumer health products, and medical devices across major therapeutic areas including cardiovascular, diabetes, respiratory, anti-infective, CNS, gastroenterology, orthopedics, women's health, and oncology. The company operates three dedicated GMP/GLP-compliant manufacturing facilities and supplies products to healthcare professionals, pharmacies, distributors, and end consumers across Pakistan and 37 international markets.

Product overview

PharmEvo Private is a Pakistani pharmaceutical company operating across four major areas: Pharmaceuticals (86 branded generic products), Nutraceuticals (15 products including vitamins, supplements, and herbal products), Consumer Health (5 OTC products), and Medical Devices (14 products including glucose monitors, blood pressure monitors, and diagnostic devices). The company also operates an e-commerce platform (mypharmevo.pk), maintains a pharmacovigilance program (MedGuard), provides R&D services with GLP and cGMP compliant facilities, and offers a Learning Management System for employee development. The pharmaceutical portfolio spans cardiovascular (X-plended, Xcept, Lowplat, Avsar, Arbi, Tansin, Telsarta, Anplag, Zilero, Sacvin, Ivadin, Zibes, Ramipace, Treatan, Byvas), diabetes care (Inosita, Erli, Galvecta, Dapwiz, EGLARO, Evopride), respiratory (Busonide, Aireez, TioCap, AirCare), anti-infectives (Azliv, EvoFix, Evopravir, Zilfom), CNS/psychiatry (Agoviz, Dipof, Duzalta, Estar, Evo Kalm, Oxivort, Voxamine, Xilica, Klevra, Paridopa), gastroenterology (Fasteso, Redexa, Vanzak, Zoltar), orthopedics/pain management (NISE, Thewril, Gouric, ActNise, Anex-M), women's health (Femova, Ibandro, Onita, Retzole, SheVit), and oncology (Bevec, Rituxim, Traszeptin). The medical device portfolio includes EVOCHECK branded glucose monitors, thermometers, and pulse oximeters, as well as distributed OMRON branded products. Manufacturing operations span three dedicated facilities: Cephalosporin, Non-Cephalosporin, and Nutraceutical, with a global presence in 37 markets.

Differentiator

Problem solved

Functional benefit

Brands

• PHARMASSIST: First ever Toll free Drug and Poison and Pharmacovigilance Centre in Pakistan, providing medication information to healthcare professionals
• ILE (Institute of Leadership Excellence)
• eDR
• Jahan-e-Maseeha
• EvoTalks
• Discovering Diabetes
• Discovering Hypertension
• Discovering PCOS
• Evolve - Wellness Academy
• Darul Kutub
• IGM (Innovation Gateway Meeting)
• MedGuard

Products and services

• Pharmaceuticals (Branded Generics Portfolio)

Quantifiable outcome

• Among top 20 pharmaceutical companies in Pakistan
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Various International Drug AuthoritiesminorOthers · 1 January 2018Manufacturing facility has acquired approval from several drug authorities where products are being exported.
• PES (Pakistan Endocrine Society)coreStrategic or Co-development PartnerJoint collaboration on Discovering Diabetes initiative for tracking and educating diabetes patients in Pakistan. The initiative aims to educate the Pakistani population for prevention, early detection, and management of diabetes.
• Healthcare Organizations and InstitutionscoreImplementation/ SI/ Consulting PartnerWin-win partnerships with Doctors, Healthcare Organizations and Medical Institutions under eDR program offering diverse value-added services in digital health space.
• International Distribution PartnerscoreChannel Partner/ Reseller/ DistributorNetwork of affiliates and partners across 37 markets including Caucasus, Africa, Central America, Central Asia, Middle East, South Asia, Southeast Asia, Southeast Europe, Southern Africa, and West Africa for branded generics and nutraceuticals distribution.
• Drug Regulatory Authority of Pakistan (DRAP)coreOthersManufacturing facility complies with regulations of DRAP (Drug Regulatory Authority of Pakistan) and has acquired approval from several international drug authorities for exported products.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Getz Pharma: Getz Pharma is one of Pakistan's largest pharmaceutical manufacturers, operating a broad branded-generic and specialty portfolio across cardiovascular, diabetes, anti-infectives, and CNS — directly comparable to PharmEvo in product mix, Pakistani manufacturing footprint, and emerging-market export orientation.
• The Searle Company Limited: Searle is a top-tier Pakistani pharma company with a comparable branded-generic and specialty portfolio spanning multiple therapeutic areas, similar GMP manufacturing infrastructure, and overlap with PharmEvo in diabetes, cardiovascular, and women's health categories.
• Hilton Pharma: Hilton Pharma is a Pakistani pharmaceutical manufacturer with a multi-therapeutic branded-generic portfolio, dedicated manufacturing facilities, and international presence — closely matching PharmEvo in scale, regulatory positioning, and target customer segments.
• Ferozsons Laboratories Limited: Ferozsons is a publicly listed Pakistani pharma company with branded generics and specialty products, manufacturing partnerships with multinationals (e.g., Gilead for hepatitis C), and export operations — comparable to PharmEvo in domestic market positioning and international business model.

Broad incumbents

• Cipla Limited: Cipla is a leading Indian multinational pharmaceutical company with a deep branded-generic and specialty portfolio overlapping PharmEvo's therapeutic focus (respiratory, cardiovascular, anti-infectives, CNS) and significant emerging-market presence — a much larger incumbent competing in many of the same export markets.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian pharma multinational with branded generics, biosimilars, and specialty products across cardiovascular, diabetes, oncology, and CNS — overlapping with PharmEvo's portfolio categories and competing directly in African and Asian emerging markets.
• Sun Pharmaceutical Industries: Sun Pharma is the largest Indian pharma company by revenue with a broad specialty and branded-generic portfolio including cardiology, diabetes, CNS, and respiratory categories that overlap with PharmEvo's core therapeutic areas — a global-scale competitor in emerging markets.
• Aurobindo Pharma: Aurobindo is a major Indian generic and specialty pharmaceutical manufacturer with extensive emerging-market presence in Africa, Asia, and the Middle East — directly comparable to PharmEvo in branded-generic positioning and geographic focus.

Regional players

• Gulf Pharmaceutical Industries (Julphar): Julphar is one of the largest pharmaceutical manufacturers in the Middle East with branded generics across cardio, diabetes, anti-infectives, and consumer health — operating from a similar regional base as PharmEvo and competing in overlapping GCC, African, and South Asian markets.
• Aspen Pharmacare Holdings: Aspen is Africa's largest pharmaceutical manufacturer with branded generics, specialty, and consumer health products across cardiovascular, diabetes, CNS, and anti-infectives — a leading emerging-market pharma peer to PharmEvo with strong presence in African markets where PharmEvo also operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/EvoTalks
• Xx.com/pharmevo

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmEvo Private